Future of the TNM classification and staging system in head and neck cancer

Head and Neck

Volumn 32, Issue 12, 2010, Pages 1693-1711

  Takes, Robert P ^a   Rinaldo, Alessandra ^b   Silver, Carl E ^c   Piccirillo, Jay F ^d   Haigentz Jr , Missak ^c   Suárez, Carlos ^e,f   Van Der Poorten, Vincent ^g   Hermans, Robert ^g   Rodrigo, Juan Pablo ^e,f   Devaney, Kenneth O ^h   Ferlito, Alfio ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF UDINE   (Italy)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h Allegiance Health ^*  (United States)

Author keywords

classification; head and neck cancer; prognostic factors; staging; TNM

Indexed keywords

CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; HEAD AND NECK CANCER; HISTOLOGY; LYMPH NODE METASTASIS; MICROMETASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SOFT TISSUE TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR VOLUME;

HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; PROGNOSIS;

EID: 77955115277     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21361     Document Type: Review

References (150)

1. Piccirillo JF, Feinstein AR,. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer 1996; 77: 834-842.
2. Altman DG, Royston P,. What do we mean by validating a prognostic model? Stat Med 2000; 19: 453-473.
3. Denoix PF,. Nomenclature classification de cancers. Bull Inst Nat Hyg (Paris) 1952; 7: 743-748.
4. Hermanek P, Sobin LH,. TNM classification of malignant tumors, 4th ed. New York: Springer, 1987.
5. Sobin LH, Wittekind CH,. International Union Against Cancer (UICC): TNM classification of malignant tumors, 6th ed. New York: Wiley, 2002.
6. Greene FL, Page D, Morrow M, et al. AJCC cancer staging manual. 6th ed. New York: Springer, 2002.
7. Gospodarowicz MK, Miller D, Groome PA, Greene FL, Logan PA, Sobin LH,. The process for continuous improvement of the TNM classification. Cancer 2004; 100: 1-5.
8. Sala O,. Tumour-host relationship and its implications in the treatment and long-term prognosis of laryngeal cancer. Critical observations on the TNM system of tumour classification. Acta Otorhinolaryngol Belg 1976; 30: 371-378.
9. Feinstein AR, Schimpff CR, Andrews JF Jr, Wells CK,. Cancer of the larynx: a new staging system and a re-appraisal of prognosis and treatment. J Chronic Dis 1977; 30: 277-305.
10. Harrison DF,. Critical look at the classification of maxillary sinus carcinomata. Ann Otol 1978; 87: 3-9.
11. Harrison DF,. Intrinsic weakness of the TNM system for classification of laryngeal cancer. ORL J Otorhinolaryngol Relat Spec 1979; 41: 241-251.
12. Pillsbury HR, Kirchner JA,. Clinical vs histopathologic staging in laryngeal cancer. Arch Otolaryngol 1979; 105: 157-159.
13. Bailey BJ,. Beyond the 'new' TNM classification. Arch Otolaryngol Head Neck Surg 1991; 117: 369-370; editorial 371.
14. Kleinsasser O,. Revision of classification of laryngeal cancer, is it long overdue? (Proposals for an improved TN-classification). J Laryngol Otol 1992; 106: 197-204.
15. Jones GW, Browman G, Goodyear M, Marcellus D, Hodson DI,. Comparison of the addition of T and N integer scores with TNM stage groups in head and neck cancer. Head Neck 1993; 15: 497-503.
16. Piccirillo JF, Wells CK, Sasaki CT, Feinstein AR,. New clinical severity staging system for cancer of the larynx. Five-year survival rates. Ann Otol Rhinol Laryngol 1994; 103: 83-92.
17. Ferlito A, Harrison DF, Bailey BJ, DeSanto LW,. Are clinical classifications for laryngeal cancer satisfactory? Ann Otol Rhinol Laryngol 1995; 104: 741-747.
18. Piccirillo JF,. Purposes, problems, and proposals for progress in cancer staging. Arch Otolaryngol Head Neck Surg 1995; 121: 145-149.
19. Snyderman CH, Wagner RL,. Superiority of the T and N integer score (TANIS) staging system for squamous cell carcinoma of the oral cavity. Otolaryngol Head Neck Surg 1995; 112: 691-694.
20. Hart AA, Mak-Kregar S, Hilgers FJ, et al. The importance of correct stage grouping in oncology. Results of a nationwide study of oropharyngeal carcinoma in The Netherlands. Cancer 1995; 75: 2656-2662.
21. Rucci L, Gammarota L, Gallo O,. Carcinoma of the anterior commissure of the larynx: II. Proposal of a new staging system. Ann Otol Rhinol Laryngol 1996; 105: 391-396.
22. Ambrosch P, Kron M, Freudenberg LS,. Clinical staging of oropharyngeal carcinoma: a critical evaluation of a new stage grouping proposal. Cancer 1998; 82: 1613-1620.
23. Singh B, Bhaya M, Zimbler M, et al. Impact of comorbidity on outcome of young patients with head and neck squamous cell carcinoma. Head Neck 1998; 20: 1-7.
24. Carinci F, Pelucchi S, Farina A, Calearo C,. A comparison between TNM and TANIS stage grouping for predicting prognosis of oral and oropharyngeal cancer. J Oral Maxillofac Surg 1998; 56: 836-837; discussion 836-837.
25. Iro H, Waldfahrer F,. Evaluation of the newly updated TNM classification of head and neck carcinoma with data from 3247 patients. Cancer 1998; 83: 2201-2207.
26. Carinci F, Farina A, Pelucchi S, Brunelli G, Pastore A, Calearo C,. Stage grouping of oropharyngeal cancer: evaluation of three systems by means of survival analysis. J Craniofac Surg 1999; 10: 73-78.
27. Pugliano FA, Piccirillo JF, Zequeira MR, Fredrickson JM, Perez CA, Simpson JR,. Symptoms as an index of biologic behavior in head and neck cancer. Otolaryngol Head Neck Surg 1999; 120: 380-386.
28. Carinci F, Farina A, Pelucchi S, et al. Stage grouping reliability: TNM '97 versus TANIS in laryngeal cancer. Otolaryngol Head Neck Surg 1999; 120: 499-501.
29. Hall SF, Groome PA, Rothwell D, Dixon PF,. Using TNM staging to predict survival in patients with squamous cell carcinoma of head & neck. Head Neck 1999; 21: 30-38.
30. Hall SF, Groome PA, Rothwell D,. The impact of comorbidity on the survival of patients with squamous cell carcinoma of the head and neck. Head Neck 2000; 22: 317-322.
31. Lydiatt WM, Shah JP, Hoffman HT,; Head and Neck Sites Task Force. American Joint Committee on Cancer. AJCC stage groupings for head and neck cancer: should we look at alternatives? A report of the Head and Neck Sites Task Force. Head Neck 2001; 23: 607-612.
32. Groome PA, Schulze KM, Mackillop WJ, et al. A comparison of published head and neck stage groupings in carcinomas of the tonsillar region. Cancer 2001; 92: 1484-1494.
33. Baatenburg de Jong RJ, Hermans J, Molenaar J, Briaire JJ, le Cessie S,. Prediction of survival in patients with head and neck cancer. Head Neck 2001; 23: 718-724.
34. Groome PA, Schulze K, Boysen M, Hall SF, Mackillop WJ,. A comparison of published head and neck stage groupings in carcinomas of the oral cavity. Head Neck 2001; 23: 613-624.
35. Groome PA, Schulze K, Boysen M, et al. A comparison of published head and neck stage groupings in laryngeal cancer using data from two countries. J Clin Epidemiol 2002; 55: 533-544.
36. Paleri V, Wight RG, Davies GR,. Impact of comorbidity on the outcome of laryngeal squamous cancer. Head Neck 2003; 25: 1019-1026.
37. Hannisdal K, Boysen M, Evensen JF,. Different prognostic indices in 310 patients with tonsillar carcinomas. Head Neck 2003; 25: 123-131.
38. Ferrier MB, Spuesens EB, Le Cessie S, Baatenburg de Jong RJ,. Comorbidity as a major risk factor for mortality and complications in head and neck surgery. Arch Otolaryngol Head Neck Surg 2005; 131: 27-32.
39. León X, Gich I, Orús C, Del Prado Venegas M, Ramón Gras J, Quer M,. Comparison of the Radiation Therapy Oncology Group recursive partitioning classification and Union Internationale Contre le Cancer TNM classification for patients with head and neck carcinoma. Head Neck 2005; 27: 248-257.
40. Holsinger FC, Diaz EM Jr,. Laryngeal preservation in the era of chemoradiation: limitations of the current AJCC staging system. Head Neck 2006; 28: 1058-1060.
41. Talmi YP,. Problems in the current TNM staging of nonmelanoma skin cancer of the head and neck. Head Neck 2007; 29: 525-527.
42. Castro MA, Dedivitis RA, Ribeiro KC,. Comorbidity measurement in patients with laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 2007; 69: 146-152.
43. Ferlito A, Rinaldo A,. The future of the TNM staging system in laryngeal cancer: time for a debate? Eur Arch Otorhinolaryngol 2008; 265: 1441-1443.
44. van der Schroeff MP, Baatenburg de Jong RJ,. Staging and prognosis in head and neck cancer. Oral Oncol 2009; 45: 356-360.
45. Hall SF, Groome PA, Irish J, O'Sullivan B,. TNM-based stage groupings in head and neck cancer: application in cancer of the hypopharynx. Head Neck 2009; 31: 1-8.
46. Arriaga M, Curtin H, Takahashi H, Hirsch BE, Kamerer DB,. Staging proposal for external auditory meatus carcinoma based on preoperative clinical examination and computed tomography findings. Ann Otol Rhinol Laryngol 1990; 99: 714-721.
47. Moody SA, Hirsch BE, Myers EN,. Squamous cell carcinoma of the external auditory canal: an evaluation of a staging system. Am J Otol 2000; 21: 582-588.
48. Spiro RH, Thaler HT, Hicks WF, Kher UA, Huvos AH, Strong EW,. The importance of clinical staging of minor salivary gland carcinoma. Am J Surg 1991; 162: 330-336.
49. Vander Poorten VL, Balm AJ, Hilgers FJ, Tan IB, Keus RB, Hart AA,. Stage as major long term outcome predictor in minor salivary gland carcinoma. Cancer 2000; 89: 1195-1204.
50. Suarez C, Llorente JL, Fernandez De Leon R, Maseda E, Lopez A,. Prognostic factors in sinonasal tumors involving the anterior skull base. Head Neck 2004; 26: 136-144.
51. Cantù G, Solero CL, Miceli R, et al. Which classification for ethmoid malignant tumors involving the anterior skull base? Head Neck 2005; 27: 224-231.
52. Woolgar JA, Rogers SN, Lowe D, Brown JS, Vaughan ED,. Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. Oral Oncol 2003; 39: 130-137.
53. Ferlito A, Rinaldo A, Devaney KO, et al. Prognostic significance of microscopic and macroscopic extracapsular spread from metastatic tumor in the cervical lymph nodes. Oral Oncol 2002; 38: 747-751.
54. Cooper JS, Porter K, Mallin K, et al. National Cancer Database report on cancer of the head and neck: 10-year update. Head Neck 2009; 31: 748-758.
55. Ferlito A, Silver CE, Bradford CR, Rinaldo A,. Neuroendocrine neoplasms of the larynx: an overview. Head Neck 2009; 31: 1634-1646.
56. Koch BB, Trask DK, Hoffman HT, et al. National survey of head and neck verrucous carcinoma: patterns of presentation, care, and outcome. Cancer 2001; 92: 110-120.
57. van der Wal JE, Leverstein H, Snow GB, Kraaijenhagen HA, van der Waal I,. Parotid gland tumors: histologic reevaluation and reclassification of 478 cases. Head Neck 1998; 20: 204-207.
58. Brandwein MS, Ivanov K, Wallace DI, et al. Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol 2001; 25: 835-845.
59. Friedmann I, Ferlito A,. Granulomas and Neoplasms of the Larynx. Churchill Livingstone, Edinburgh; 1988.
60. Carbone A, Gloghini A, Rinaldo A, Devaney KO, Tubbs R, Ferlito A,. True identity by immunohistochemistry and molecular morphology of undifferentiated malignancies of the head and neck. Head Neck 2009; 31: 949-961.
61. Feinstein AR, Sosin DM, Wells CK,. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985; 312: 1604-1608.
62. Champion GA, Piccirillo JF,. The impact of computed tomography on pretherapeutic staging in patients with laryngeal cancer: demonstration of the Will Rogers' phenomenon. Head Neck 2004; 26: 972-976.
63. Elsheikh MN, Rinaldo A, Hamakawa H, et al. Importance of molecular analysis in detecting cervical lymph node metastasis in head and neck squamous cell carcinoma. Head Neck 2006; 28: 842-849.
64. Becker MT, Shores CG, Yu KK, Yarbrough WG,. Molecular assay to detect metastatic head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004; 130: 21-27.
65. Ferlito A, Rinaldo A, Devaney KO, Nakashiro K, Hamakawa H,. Detection of lymph node micrometastases in patients with squamous carcinoma of the head and neck. Eur Arch Otorhinolaryngol 2008; 265: 1147-1153.
66. Ferlito A, Devaney KO, Rinaldo A,. Is it time to develop an 'ultrastaging system' for use in patients with head and neck malignancies? Laryngoscope 2001; 111: 185-186.
67. Jose J, Ferlito A, Rodrigo JP, Devaney KO, Rinaldo A, MacLennan K,. Soft tissue deposits from head and neck cancer: an under-recognised prognostic factor? J Laryngol Otol 2007; 121: 1115-1117.
68. Ljumanovic R, Langendijk JA, Hoekstra OS, Leemans CR, Castelijns JA,. Distant metastases in head and neck carcinoma: identification of prognostic groups with MR imaging. Eur J Radiol 2006; 60: 58-66.
69. Chua DT, Sham JS, Kwong DL, et al. Volumetric analysis of tumor extent in nasopharyngeal carcinoma and correlation with treatment outcome. Int J Radiat Oncol Biol Phys 1997; 39: 711-719.
70. Pameijer FA, Mancuso AA, Mendenhall WM, et al. Evaluation of pretreatment computed tomography as a predictor of local control in T1/T2 pyriform sinus carcinoma treated with definitive radiotherapy. Head Neck 1998; 20: 159-168.
71. Hermans R, Van den Bogaert W, Rijnders A, Baert AL,. Value of computed tomography as outcome predictor of supraglottic squamous cell carcinoma treated by definitive radiation therapy. Int J Radiat Oncol Biol Phys 1999; 44: 755-765.
72. Hermans R, Van den Bogaert W, Rijnders A, Doornaert P, Baert AL,. Predicting the local outcome of glottic squamous cell carcinoma after definitive radiation therapy: value of computed tomography-determined tumour parameters. Radiother Oncol 1999; 50: 39-46.
73. Mancuso AA, Mukherji SK, Schmalfuss I, et al. Preradiotherapy computed tomography as a predictor of local control in supraglottic carcinoma. J Clin Oncol 1999; 17: 631-637.
74. Chong VF, Zhou JY, Khoo JB, Huang J, Lim TK,. Nasopharyngeal carcinoma tumor volume measurement. Radiology 2004; 231: 914-921.
75. Hoebers FJ, Pameijer FA, de Bois J, et al. Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma. Head Neck 2008; 30: 1216-1223.
76. Chapman JD, Bradley JD, Eary JF, et al. Molecular (functional) imaging for radiotherapy applications: an RTOG symposium. Int J Radiat Oncol Biol Phys 2003; 55: 294-301.
77. Ling CC, Humm J, Larson S, et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 2000; 47: 551-560.
78. Nordsmark M, Overgaard J,. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000; 57: 39-43.
79. Kaanders JH, Bussink J, van der Kogel AJ,. ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002; 3: 728-737.
80. Hermans R, Meijerink M, Van den Bogaert W, Rijnders A, Weltens C, Lambin P,. Tumor perfusion rate determined noninvasively by dynamic computed tomography predicts outcome in head-and-neck cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2003; 57: 1351-1356.
81. Vandecaveye V, De Keyzer F, Vander Poorten V, et al. Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology 2009; 251: 134-146.
82. Bisdas S, Nguyen SA, Anand SK, Glavina G, Day T, Rumboldt Z,. Outcome prediction after surgery and chemoradiation of squamous cell carcinoma in the oral cavity, oropharynx, and hypopharynx: use of baseline perfusion CT microcirculatory parameters vs. tumor volume. Int J Radiat Oncol Biol Phys 2009; 73: 1313-1318.
83. Kim S, Loevner L, Quon H, et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck. Clin Cancer Res 2009; 15: 986-994.
84. Rischin D, Hicks RJ, Fisher R, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006; 24: 2098-2104.
85. Vander Poorten VL, Balm AJ, Hilgers FJ, et al. The development of a prognostic score for patients with parotid carcinoma. Cancer 1999; 85: 2057-2067.
86. Spiro RH,. Management of malignant tumors of the salivary glands. Oncology 1998; 12: 671-683.
87. Michels JJ, Jacques M, Henry-Amar M, Bardet S,. Prevalence and prognostic significance of tall cell variant of papillary thyroid carcinoma. Hum Pathol 2007; 38: 212-219.
88. Spiro RH, Guillamondegui O Jr, Paulino AF, Huvos AG,. Pattern of invasion and margin assessment in patients with oral tongue cancer. Head Neck 1999; 21: 408-413.
89. O-charoenrat P, Pillai G, Patel S, et al. Tumour thickness predicts cervical nodal metastases and survival in early oral tongue cancer. Oral Oncol 2003; 39: 386-390.
90. Bryne M, Koppang HS, Lilleng R, Kjaerheim A,. Malignancy grading of the deep invasive margins of oral squamous cell carcinomas has high prognostic value. J Pathol 1992; 166: 375-381.
91. Gluckman JL, Pavelic ZP, Welkoborsky HJ, et al. Prognostic indicators for squamous cell carcinoma of the oral cavity: a clinicopathologic correlation. Laryngoscope 1997; 107: 1239-1244.
92. Weijers M, Snow GB, Bezemer PD, van der Waal I,. Malignancy grading is no better than conventional histopathological grading in small squamous cell carcinoma of tongue and floor of mouth: retrospective study in 128 patients. J Oral Pathol Med 2009; 38: 343-347.
93. Clark JR, Naranjo N, Franklin JH, de Almeida J, Gullane PJ,. Established prognostic variables in N0 oral carcinoma. Otolaryngol Head Neck Surg 2006; 135: 748-753.
94. Vander Poorten V, Hart A, Vauterin T, et al. Prognostic index for patients with parotid carcinoma: international external validation in a Belgian-German database. Cancer 2009; 115: 540-550.
95. Shah JP,. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg 1990; 160: 405-409.
96. Patel SG, Shah JP,. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin 2005; 55: 242-258.
97. Hermanek P, Hutter RV, Sobin LH, Wittekind C,. International Union Against Cancer. Classification of isolated tumor cells and micrometastasis. Cancer 1999; 86: 2668-2673.
98. Cserni G, Amendoeira I, Apostolikas N, et al. Discrepancies in current practice of pathological evaluation of sentinel lymph nodes in breast cancer. Results of a questionnaire based survey by the European Working Group for Breast Screening Pathology. J Clin Pathol 2004; 57: 695-701.
99. van Akkooi AC, de Wilt JH, Verhoef C, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 2006; 17: 1578-1585.
100. van Akkooi AC, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg 2008; 248: 949-955.
101. Ollila DW, Ashburn JH, Amos KD, et al. Metastatic melanoma cells in the sentinel node cannot be ignored. J Am Coll Surg 2009; 208: 924-929; discussion 919-930.
102. Devaney KO, Rinaldo A, Ferlito A,. Micrometastases in cervical lymph nodes from patients with squamous carcinoma of the head and neck: should they be actively sought? Maybe. Am J Otolaryngol 2007; 28: 271-274.
103. Greene FL, Sobin LH,. The staging of cancer: a retrospective and prospective appraisal. CA Cancer J Clin 2008; 58: 180-190.
104. Atula T, Hunter KD, Cooper LA, Shoaib T, Ross GL, Soutar DS,. Micrometastases and isolated tumour cells in sentinel lymph nodes in oral and oropharyngeal squamous cell carcinoma. Eur J Surg Oncol 2009; 35: 532-538.
105. Takes RP, Rinaldo A, Rodrigo JP, Devaney KO, Fagan JJ, Ferlito A,. Can biomarkers play a role in the decision about treatment of the clinically negative neck in patients with head and neck cancer? Head Neck 2008; 30: 525-538.
106. Chiang AC, Massagué J,. Molecular basis of metastasis. N Engl J Med 2008; 359: 2814-2823.
107. Chung CH, Parker JS, Karaca G, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004; 5: 489-500.
108. Pramana J, Van den Brekel MW, van Velthuysen ML, et al. Gene expression profiling to predict outcome after chemoradiation in head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69: 1544-1552.
109. Roepman P, Wessels LF, Kettelarij N, et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 2005; 37: 182-186.
110. D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML,. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009; 199: 1263-1269.
111. Cohan DM, Popat S, Kaplan SE, Rigual N, Loree T, Hicks WL Jr,. Oropharyngeal cancer: current understanding and management. Curr Opin Otolaryngol Head Neck Surg 2009; 17: 88-94.
112. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269.
113. Vidal L, Gillison ML,. Human papillomavirus in HNSCC: recognition of a distinct disease type. Hematol Oncol Clin North Am 2008; 22: 1125-1142.
114. Greene FL, Sobin LH,. A worldwide approach to the TNM staging system: collaborative efforts of the AJCC and UICC. J Surg Oncol 2009; 99: 269-272.
115. Ludwig JA, Weinstein JN,. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005; 5: 845-856.
116. Preciado DA, Matas A, Adams GL,. Squamous cell carcinoma of the head and neck in solid organ transplant recipients. Head Neck 2002; 24: 319-325.
117. Kutler DI, Auerbach AD, Satagopan J, et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 2003; 129: 106-112.
118. Singh B, Balwally AN, Shaha AR, Rosenfeld RM, Har-El G, Lucente FE,. Upper aerodigestive tract squamous cell carcinoma. The human immunodeficiency virus connection. Arch Otolaryngol Head Neck Surg 1996; 122: 639-643.
119. Haigentz M Jr,. Aerodigestive cancers in HIV infection. Curr Opin Oncol 2005; 17: 474-478.
120. Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL,. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001; 91: 2136-2147.
121. Hathaway B, Landsittel DP, Gooding W, et al. Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. Laryngoscope 2005; 115: 522-527.
122. Lacy PD, Piccirillo JF, Merritt MG, Zequeira MR,. Head and neck squamous cell carcinoma: better to be young. Otolaryngol Head Neck Surg 2000; 122: 253-258.
123. Bhattacharyya N,. A matched survival analysis for squamous cell carcinoma of the head and neck in the elderly. Laryngoscope 2003; 113: 368-372.
124. Dikshit RP, Boffetta P, Bouchardy C, et al. Lifestyle habits as prognostic factors in survival of laryngeal and hypopharyngeal cancer: a multicentric European study. Int J Cancer 2005; 117: 992-995.
125. Kokoska MS, Piccirillo JF, Haughey BH,. Gender differences in cancer of the larynx. Ann Otol Rhinol Laryngol 1995; 104: 419-424.
126. Faye-Lund H, Abdelnoor M,. Prognostic factors of survival in a cohort of head and neck cancer patients in Oslo. Eur J Cancer Part B Oral Oncol 1996; 32B: 83-90.
127. McLean A, LeMay W, Vila P, Wegner M, Remington P,. Disparities in oral and pharyngeal cancer incidence and mortality among Wisconsin residents, 1999-2002. WMJ 2006; 105: 32-35.
128. Hafkamp HC, Manni JJ, Haesevoets A, et al. Marked differences in survival rate between smokers and nonsmokers with HPV 16-associated tonsillar carcinomas. Int J Cancer 2008; 122: 2656-2664.
129. van Bokhorst-de van der Schuer, van Leeuwen PA, Kuik DJ, et al. The impact of nutritional status on the prognoses of patients with advanced head and neck cancer. Cancer 1999; 86: 519-527.
130. Ravasco P, Monteiro-Grillo I, Marques Vidal P, Camilo ME,. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 2005; 27: 659-668.
131. Sanabria A, Carvalho AL, Vartanian JG, Magrin J, Ikeda MK, Kowalski LP,. Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol 2007; 14: 1449-1457.
132. Hall SF, Rochon PA, Streiner DL, Paszat LF, Groome PA, Rohland SL,. Measuring comorbidity in patients with head and neck cancer. Laryngoscope 2002; 112: 1988-1996.
133. Piccirillo JF, Vlahiotis A,. Comorbidity in patients with cancer of the head and neck: prevalence and impact on treatment and prognosis. Curr Oncol Rep 2006; 8: 123-129.
134. Homma A, Sakashita T, Oridate N, et al. Importance of comorbidity in hypopharyngeal cancer. Head Neck 2010; 32: 148-153.
135. Charlson M, Szatrowski TP, Peterson J, Gold J,. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-1251.
136. Elixhauser A, Steiner C, Harris DR, Coffey RM,. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8-27.
137. Reid BC, Alberg AJ, Klassen AC, et al. A comparison of three comorbidity indexes in a head and neck cancer population. Oral Oncology 2002; 38: 187-194.
138. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM,. How to measure comorbidity. A critical review of available methods. J Clin Epidemiol 2003; 56: 221-229.
139. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr,. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004; 291: 2441-2447.
140. Feinstein AR, Wells CK,. A clinical-severity staging system for patients with lung cancer. Medicine (Baltimore) 1990; 69: 1-33.
141. Piccirillo JF,. Importance of comorbidity in head and neck cancer. Laryngoscope 2000; 110: 593-602.
142. Piccirillo JF,. Inclusion of comorbidity in a staging system for head and neck cancer. Oncology (Williston Park) 1995; 9: 831-836; discussion 841, 845-848.
143. Begg CB, Cramer LD, Hoskins WJ, Brennan MF,. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998; 280: 1747-1751.
144. Hillner BE, Smith TJ, Desch CE,. Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol 2000; 18: 2327-2340.
145. Freeman HP,. Poverty, culture, and social injustice: determinants of cancer disparities. CA Cancer J Clin 2004; 54: 72-77.
146. Janssen-Heijnen ML, Houterman S, Lemmens VE, Brenner H, Steyerberg EW, Coebergh JW,. Prognosis for long-term survivors of cancer. Ann Oncol 2007; 18: 1408-1413.
147. Eckel HE,. Comments on the editorial by Ferlito and Rinaldo: "The future of TNM staging system in laryngeal cancer: time for a debate?" Eur Arch Otorhinolaryngol 2008; 265: 1445-1446.
148. Manikantan K, Sayed SI, Syrigos KN, et al. Challenges for the future modifications of the TNM staging system for head and neck cancer: case for a new computational model? Cancer Treat Rev 2009; 35: 639-644.
149. Greene FL, Sobin LH,. The TNM system: our language for cancer care. J Surg Oncol 2002; 80: 119-120.
150. Greene FL,. A cancer staging perspective: the value of anatomical staging. J Surg Oncol 2007; 95: 6-7.